Quick Read – Pfizer’s 7% yield and forward P/E of 8 complement Viatris’s three FDA PDUFA decisions arriving before year-end 2026. – Kimberly-Clark’s pending acquisition of Kenvue at $3.50 cash plus shares gives holders a defined takeout floor with shareholder approval already…
cured. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Pfizer didn’t make the cut. Grab the names FREE today
Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance. For retail investors scanning for value, the sub-$30 shelf in healthcare currently offers exposure to a pending strategic buyout, a 7% dividend yield backed by a reaffirmed outlook, and a restructuring story with multiple near-term FDA catalysts. That is a lot of optionality for very little share price.
With that in mind, here are three healthcare stocks trading under $30 that look attractively priced heading into the back half of 2026. Kenvue (NYSE: KVUE) Kenvue (NYSE:KVUE) is the consumer health company spun off from Johnson & Johnson (NYSE:JNJ), home to Tylenol, Neutrogena, Aveeno, Listerine, BAND-AID, Zyrtec, and Nicorette. Shares closed the last session at $19.83, comfortably under the $30 ceiling and up 17.65% year to date, which still leaves the stock below its 52-week high of $21.85.